Company News
02/22/2022
CEE to Host STEM Lyceums Events for Students
McLean, Va. – The Center for Excellence in Education (CEE) announces its spring 2022 schedule of virtual science, technology, engineering, and mathematics (STEM) Lyceums events for high school students. CEE’s STEM Lyceums are free monthly virtual meetings that will engage high school students in discussion and exploration of STEM concepts and unique STEM career pathways, provided …
02/16/2022
Children’s National uses HIFU to perform first ever non-invasive brain tumor surgery
Washington, D.C., Children’s National Hospital successfully performed the first-ever high-intensity focused ultrasound (HIFU) surgery on a pediatric patient with neurofibromatosis (NF). This is the youngest patient to undergo HIFU treatment in the world. The advancement of children’s medical devices in the U.S. continues to significantly lag behind adult devices. This is why this milestone marks …
02/16/2022
TearSolutions, Inc. Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Lacripep™
CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — TearSolutions, Inc. (“the Company”), a privately held developer of a replacement therapy for the treatment of Dry Eye Disease (DED) called Lacripep, today announced that in late 2021 it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Lacripep …
02/16/2022
ADIAL PHARMACEUTICALS ANNOUNCES CLOSING OF $10 MILLION FINANCING
CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately $10 million of …
02/16/2022
ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin
CHARLOTTESVILLE, Va., /PRNewswire/ — ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer through its innovative ZielFind drug discovery platform, today announced the first patient dosed in its Phase 1/2 clinical trial. The study will evaluate ZB131 in patients with solid tumors who are either non-responsive to or ineligible for the standard …
02/16/2022
ATCC Announces Awards from DTRA that Strengthen ATCC’s Antiviral Drug Discovery and Development Portfolio for Global Health and Biodefense
Manassas, VA, ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA). The work will identify and characterize novel therapeutic approaches to viruses of global health concern. Promising therapeutic candidates will be tested for efficacy with …